# A Research Study to Compare Insulin 287 Once a Week to Insulin Glargine (100 Units/mL) Once a Day in People With Type 2 Diabetes.

> **NCT03751657** · PHASE2 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 247 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Insulin icodec
- **DRUG:** Placebo (insulin 287)
- **DRUG:** Metformin
- **DRUG:** Dipeptidyl peptidase-4 inhibitors
- **DRUG:** Insulin glargine
- **DRUG:** Placebo (insulin glargine)

## Key facts

- **NCT ID:** NCT03751657
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-29
- **Primary completion:** 2019-12-16
- **Final completion:** 2020-01-17
- **Target enrollment:** 247 (ACTUAL)
- **Last updated:** 2021-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03751657

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03751657, "A Research Study to Compare Insulin 287 Once a Week to Insulin Glargine (100 Units/mL) Once a Day in People With Type 2 Diabetes.". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03751657. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*